Loading
Latest filing published 05 Dec 2025 for Enanta Pharmaceuticals INC, €6,624.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Harry R. Trout III is a declared insider of Enanta Pharmaceuticals Inc, with filings sourced from SEC (Form 4). Between 25 November 2025 and 5 December 2025, the trades on record add up to 4 filings.
No open-market purchase appears, only 2 sales worth €11k. The rest of the record consists of 2 share grants.
On 5 December 2025 came the latest disclosure, an open-market sale for €6,624 in Enanta Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations